The Discovery Process Chemistry (DPC) Model: A Cross-Pharma Perspective
Discovery Process Chemistry (DPC) has emerged as a critical bridge between discovery chemistry and chemical development that allows more seamless progression of drug candidates to the clinic. DPC aims to accelerate projects by integrating SAR-enabling methodologies, scalable route design to inform later campaigns, and early material delivery. Case studies from MSD, Johnson & Johnson, and AstraZeneca highlight how this model can drive innovation and mitigate risks at the interface between medicinal and process chemistry groups. Keywords: discovery process, route scouting, early scale-up, and SAR enabling.
Authors
- Damien Valette (ORCID: https://orcid.org/0000-0002-1620-3502)
- Peter J. Lindsay‐Scott (ORCID: https://orcid.org/0000-0002-4721-3594)
- Matthieu Jouffroy (ORCID: https://orcid.org/0000-0003-4478-2502)
- Hilmar Weinmann
- Thomas M. McGuire (ORCID: https://orcid.org/0000-0002-2719-1228)
- Jonathan M. E. Hughes (ORCID: https://orcid.org/0000-0002-5708-2882)
- Joseph M. Bateman (ORCID: https://orcid.org/0000-0001-5330-5607)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Johnson & Johnson (United States) (US)
- Janssen (Belgium) (BE)
- MSD (UK) Limited (United Kingdom) (GB)
Publication Details
- Journal
- Organic Process Research & Development
- Published
- 2026-07-17
- DOI
- https://doi.org/10.1021/acs.oprd.6c00218
- Primary Topic
- Chemistry and Chemical Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00